ReviewCurrent protein & peptide science2026
From CASP13 to the Nobel Prize: DeepMind's AlphaFold Journey in Revolutionizing Protein Structure Prediction and Beyond.
Review in Current protein & peptide science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The promise of AlphaFold for gene structure annotation.Nucleic acids research · 2026Article
- AI-aided engineering and production optimization of chimeric hetero-viral capping enzymes for mRNA vaccines.Scientific reports · 2026Article
- Signal peptidase complex mediates rotavirus VP7 processing and virion assembly.PLoS pathogens · 2026Article
- Editorial: Advancements in P2X7 antagonists: from mechanistic insights to therapeutic applications.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Four years ago, at the 14th Critical Assessment of Structure Prediction (CASP14), John Moult made a historic announcement that the long-standing challenge of Protein Structure Prediction- a problem that had confounded scientists for over five decades-had been "solved" for single protein chains. Supporting this groundbreaking statement was a plot depicting the median Global Distance Test (GDT) across 87 out of 92 domains, where AlphaFold2, developed by DeepMind, achieved an unprecedented score of 92.4. The bar chart not only underscored AlphaFold2' s remarkable performance-standing out prominently among other methods-but also revealed a level of accuracy that exceeded all prior expectations. In the years since this breakthrough, DeepMind's team has made significant strides. The AlphaFold Database now hosts approximately 214 million structures for various model organisms, covering nearly the entire genome. Research continues to explore multiple facets of protein science, including the prediction of multi-chain protein complex structures and the impact of missense mutations on protein function. The open availability of this extensive database and the suite of AlphaFold2 algorithms has catalysed remarkable advancements in protein biology and bioinformatics. This review will begin by revisiting DeepMind's early efforts in CASP13, detailing the architecture and the remarkable progress that led to their breakthrough of AlphaFold2 in CASP14 (2020). It will then delve into two main areas: (1) AlphaFold's contributions to the scientific community across various fields over the past four years, and (2) the latest improvements, enhancements, and achievements by DeepMind, including AlphaFold3 and the Nobel Prize in Chemistry.
Indexed as
Identifiers
41047692What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.